Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Immunome Inc. (IMNM) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Immunome Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1472012.
Total stock buying since 2020: $8,732,504.
Total stock sales since 2020: $279,294.
Total stock option exercises since 2020: $104,140.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 311,400 | $2,369,895 | 0 | $0 | 5,200 | $7,020 |
| 2024 | 143,805 | $1,407,614 | 17,904 | $279,294 | 61,524 | $70,457 |
| 2023 | 211,504 | $1,249,988 | 0 | $0 | 0 | $0 |
| 2021 | 146,000 | $2,705,023 | 0 | $0 | 2,343 | $26,663 |
| 2020 | 83,332 | $999,984 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 5,000 | $46,900 | 0 | $0 | 0 | $0 |
| 2025-03 | 156,400 | $1,160,495 | 0 | $0 | 5,200 | $7,020 |
| 2025-01 | 150,000 | $1,162,500 | 0 | $0 | 0 | $0 |
| 2024-11 | 136,805 | $1,310,006 | 0 | $0 | 0 | $0 |
| 2024-09 | 0 | $0 | 14,380 | $230,223 | 42,000 | $44,100 |
| 2024-08 | 7,000 | $97,608 | 3,524 | $49,071 | 19,524 | $26,357 |
| 2023-10 | 211,504 | $1,249,988 | 0 | $0 | 0 | $0 |
| 2021-09 | 71,912 | $1,341,453 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 0 | $0 | 2,343 | $26,663 |
| 2021-05 | 74,088 | $1,363,570 | 0 | $0 | 0 | $0 |
| 2020-10 | 83,332 | $999,984 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-03 | Bienaime Jean Jacques | Buy | 5,000 | 9.38 | 46,900 |
| 2025-03-27 | Higgins Jack (Chief Scientific Officer) | Option Ex | 5,200 | 1.35 | 7,020 |
| 2025-03-26 | Siegall Clay B (President and CEO) | Buy | 137,100 | 7.29 | 999,459 |
| 2025-03-24 | Tsai Philip (Chief Technology Officer) | Buy | 12,300 | 8.42 | 103,566 |
| 2025-03-24 | Bienaime Jean Jacques | Buy | 7,000 | 8.21 | 57,470 |
| 2025-01-31 | Siegall Clay B (President and CEO) | Buy | 150,000 | 7.75 | 1,162,500 |
| 2024-11-22 | Siegall Clay B (President and CEO) | Buy | 33,943 | 9.78 | 331,928 |
| 2024-11-21 | Tsai Philip (Chief Technology Officer) | Buy | 21,000 | 9.43 | 198,030 |
| 2024-11-21 | Lechleider Robert (Chief Medical Officer) | Buy | 15,805 | 9.48 | 149,799 |
| 2024-11-21 | Siegall Clay B (President and CEO) | Buy | 66,057 | 9.54 | 630,249 |
| 2024-09-19 | Rosett Max (Chief Financial Officer) | Sale | 14,380 | 16.01 | 230,223 |
| 2024-09-19 | Rosett Max (Chief Financial Officer) | Option Ex | 42,000 | 1.05 | 44,100 |
| 2024-08-16 | Bienaime Jean Jacques | Buy | 7,000 | 13.94 | 97,608 |
| 2024-08-15 | Higgins Jack (Chief Scientific Officer) | Sale | 3,524 | 13.93 | 49,071 |
| 2024-08-15 | Higgins Jack (Chief Scientific Officer) | Option Ex | 19,524 | 1.35 | 26,357 |
| 2023-10-02 | Turner Bruce (Chief Strategy Officer) | Buy | 42,300 | 5.91 | 249,993 |
| 2023-10-02 | Siegall Clay B (President and CEO) | Buy | 169,204 | 5.91 | 999,995 |
| 2021-09-13 | Rapp Michael | Buy | 25,962 | 19.96 | 518,201 |
| 2021-09-10 | Rapp Michael | Buy | 15,500 | 17.85 | 276,675 |
| 2021-09-09 | Rapp Michael | Buy | 30,450 | 17.95 | 546,577 |
| 2021-08-18 | Baron Richard A | Option Ex | 2,343 | 11.38 | 26,663 |
| 2021-05-26 | Lefenfeld Michael | Buy | 1,335 | 19.03 | 25,405 |
| 2021-05-26 | Rapp Michael | Buy | 2,300 | 18.94 | 43,562 |
| 2021-05-25 | Lefenfeld Michael | Buy | 2,715 | 18.44 | 50,064 |
| 2021-05-25 | Sarma Purnanand D (President and CEO) | Buy | 10,500 | 18.41 | 193,305 |
| 2021-05-25 | Rapp Michael | Buy | 19,303 | 18.32 | 353,630 |
| 2021-05-24 | Lefenfeld Michael | Buy | 600 | 17.80 | 10,680 |
| 2021-05-24 | Rapp Michael | Buy | 31,895 | 18.38 | 586,230 |
| 2021-05-24 | Lamattina John L | Buy | 5,440 | 18.51 | 100,694 |
| 2020-10-06 | Rapp Michael (Director) | Buy | 83,332 | 12.00 | 999,984 |
Insider trading activities including stock purchases, stock sales, and option exercises of IMNM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Immunome Inc. (symbol IMNM, CIK number 1472012) see the Securities and Exchange Commission (SEC) website.